Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings

Background  Rivaroxaban monotherapy was noninferior to combination therapy (rivaroxaban plus antiplatelet therapy) in efficacy but superior in safety in the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial. Among 2,215 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arashi, Hiroyuki, Yamaguchi, Junichi, Hagiwara, Nobuhisa, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Miyauchi, Katsumi, Kimura, Kazuo, Hirayama, Atsushi, Matsui, Kunihiko, Ogawa, Hisao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420554/
https://www.ncbi.nlm.nih.gov/pubmed/35697255
http://dx.doi.org/10.1055/s-0042-1744543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420554/
https://www.ncbi.nlm.nih.gov/pubmed/35697255
http://dx.doi.org/10.1055/s-0042-1744543

Ejemplares similares